In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with David Moss, MBA, CEO of INmune Bio, a company developing a new class of dominant-negative inhibitors that target innate immune pathways driving chronic inflammation in serious diseases.
The company’s key programs include an off-the-shelf, umbilical cord-derived cell therapy being developed for recessive dystrophic epidermolysis bullosa (RDEB), which is one of the rarest and most debilitating genetic skin diseases. The company is also developing a next-generation innate immune modulator for neurodegenerative conditions such as Alzheimer’s.
David has been in biotech for over 30 years, starting his career in San Diego, which then took him to different cities across the US. He served as CFO of INmune Bio since the formation of the company in September 2015. He has founded, funded and taken public various companies in a variety of industries since 1995.
David was a founding investor in Reliant Service Group LLC, which was acquired in 2015 by a leading private equity firm. He previously served as Managing Director, Corporate Finance for a New York-based securities firm, where he advised companies on corporate strategy, financings and business development. Prior to these roles, he served as Managing Partner at a Seattle-based venture capital firm.
David holds an MBA from Rice University and a BA in Economics from the University of California, San Diego.
Tune in to learn more about the potential of bolstering innate immunity therapeutically in diseases driven by chronic inflammation.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN